Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 9/2020

Inhalt (21 Artikel)

Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site

  • Review

Elaheh Nasrollahzadeh, Sepideh Razi, Mahsa Keshavarz-Fathi, Massimiliano Mazzone, Nima Rezaei

IL-12 regulates the expansion, phenotype, and function of murine NK cells activated by IL-15 and IL-18

  • Original Article

Naoto Oka, Tzvetanka Markova, Kenzo Tsuzuki, Wen Li, Yosif El-Darawish, Magdalena Pencheva-Demireva, Kyousuke Yamanishi, Hiromichi Yamanishi, Masafumi Sakagami, Yoshimasa Tanaka, Haruki Okamura

Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study

  • Open Access
  • Original Article

Lujun Shen, Han Qi, Shuanggang Chen, Fei Cao, Lin Xie, Ying Wu, Weimei Ma, Ze Song, Hui Yuan, Tao Zhang, Dandan Li, Xizhi Wen, Qifeng Chen, Wang Li, Xiaoshi Zhang, Weijun Fan

Combining doxorubicin with stearylamine-bearing liposomes elicits Th1 cytokine responses and cures metastasis in a mouse model

  • Original Article

Manjarika De, Sneha Ghosh, Mohammad Asad, Indranil Banerjee, Nahid Ali

In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy

  • Original Article

Lukas Marcelis, Asier Antoranz, Anne-Marie Delsupehe, Pauline Biesemans, Julio Finalet Ferreiro, Koen Debackere, Peter Vandenberghe, Gregor Verhoef, Olivier Gheysens, Giorgio Cattoretti, Francesca Maria Bosisio, Xavier Sagaert, Daan Dierickx, Thomas Tousseyn

Patients’ NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing

  • Original Article

Assila Belounis, Marina Ayoub, Paulo Cordeiro, William Lemieux, Pierre Teira, Elie Haddad, Sabine Herblot, Michel Duval

Blockade of CD73 delays glioblastoma growth by modulating the immune environment

  • Original Article

J. H. Azambuja, R. S. Schuh, L. R. Michels, I. C. Iser, L. R. Beckenkamp, G. G. Roliano, G. S. Lenz, J. N. Scholl, J. Sévigny, M. R. Wink, M. A. Stefani, A. M. O. Battastini, F. Figueiró, H. F. Teixeira, E. Braganhol

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

  • Open Access
  • Original Article

Lihong Peng, Yong Wang, Fen Liu, Xiaotong Qiu, Xinwei Zhang, Chen Fang, Xiaoyin Qian, Yong Li

Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature

  • Open Access
  • Original Article

Tsubasa Watanabe, Elke Firat, Jutta Scholber, Simone Gaedicke, Corinne Heinrich, Ren Luo, Nicolas Ehrat, Gabriele Multhoff, Annette Schmitt-Graeff, Anca-Ligia Grosu, Amir Abdollahi, Jessica C. Hassel, Dagmar von Bubnoff, Frank Meiss, Gabriele Niedermann

Comparative immunomodulatory properties of mesenchymal stem cells derived from human breast tumor and normal breast adipose tissue

  • Original Article

Koushan Sineh Sepehr, Alireza Razavi, Zuhair Mohammad Hassan, Abdolreza Fazel, Meghdad Abdollahpour-Alitappeh, Majid Mossahebi-Mohammadi, Mir Saeed Yekaninejad, Behrouz Farhadihosseinabadi, Seyed Mahmoud Hashemi

CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer

  • Original Article

Tao Wang, Quan Zhou, Han Zeng, Hongyu Zhang, Zhaopei Liu, Jialiang Shao, Zewei Wang, Ying Xiong, Jiajun Wang, Qi Bai, Yu Xia, Yiwei Wang, Li Liu, Yu Zhu, Le Xu, Bo Dai, Jianming Guo, Yuan Chang, Xiang Wang, Jiejie Xu

Cysteine cathepsins L and X differentially modulate interactions between myeloid-derived suppressor cells and tumor cells

  • Original Article

Tanja Jakoš, Anja Pišlar, Urša Pečar Fonović, Urban Švajger, Janko Kos

A gene expression-based immune signature for lung adenocarcinoma prognosis

  • Original Article

Lijuan Wang, Xizhi Luo, Chao Cheng, Christopher I. Amos, Guoshuai Cai, Feifei Xiao

Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells

  • Original Article

Yihe Yan, Leting Zheng, Qiang Du, Bing Yan, David A. Geller

Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone

  • Original Article

Jasna Metovic, Laura Annaratone, Alessandra Linari, Simona Osella-Abate, Chiara Musuraca, Francesca Veneziano, Chiara Vignale, Luca Bertero, Paola Cassoni, Nicola Ratto, Alessandro Comandone, Giovanni Grignani, Raimondo Piana, Mauro Papotti

Aberrant peripheral blood CD4+ CD25+ FOXP3+ regulatory T cells/T helper-17 number is associated with the outcome of patients with lymphoma

  • Original Article

Mehdi Dehghani, Mehdi Kalani, Hossein Golmoghaddam, Mani Ramzi, Nargess Arandi

Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors

  • Research Report

Ayumi Hashimoto, Takeshi Fukumoto, Rugang Zhang, Dmitry Gabrilovich

Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy

  • Letter to the Editors

Melissa J. Danesh, Patrick M. Mulvaney, Naoka Murakami, Leonardo V. Riella, Ann W. Silk, Glenn J. Hanna, Chrysalyne D. Schmults

Neu im Fachgebiet Onkologie

ctDNA erkennt minimale Resterkrankung beim Melanom

Die Diagnose einer minimalen Resterkrankung mithilfe zirkulierender Tumor-DNA könnte (ctDNA) auch das Management von Patientinnen und Patienten mit Melanomen im Stadium III bereichern, wie Ergebnisse einer Studie nahelegen – auch wenn die Methode noch nicht perfekt funktioniert.

Höhere Dosis von Dexamethason senkt Überlebenschancen

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Ringen um den richtigen Umgang mit Zufallsbefunden

Wenn 2026 in Deutschland das Lungenkrebsscreening mittels Low-Dose-Computertomografie (LDCT) eingeführt wird, wird es auch viele Zufallsbefunde ans Licht bringen. Das birgt Chancen und Risiken.

Bald 5% der Krebserkrankungen durch CT verursacht

Die jährlich rund 93 Millionen CTs in den USA könnten künftig zu über 100.000 zusätzlichen Krebserkrankungen führen, geht aus einer Modellrechnung hervor. Damit würde eine von 20 Krebserkrankungen auf die ionisierende Strahlung bei CT-Untersuchungen zurückgehen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.